Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window An oncolytic ...

Merck & Co’s $394 million acquisition of Viralytics has stoked interest in oncolytic viruses, a class of drugs that have been in the shadow of the checkpoint inhibitors and CAR-T therapies that ...

The research article, “An oncolytic virus–T cell chimera for cancer immunotherapy,” was published in Nature Biotechnology. Among the newer forms of immunotherapy for cancer treatment ...

Oncolytic viruses, once considered medical curiosities, are now cutting-edge tools in the fight against some of the most challenging cancers, like glioblastoma. These tiny engineered viruses ...

Investigators from Brigham and Women’s Hospital reported the results of a Phase I clinical trial evaluating a novel engineered oncolytic herpes virus (oHSV) in patients with high-grade recurrent ...

Oncolytic virus (OV)-based immunotherapy has emerged as a promising strategy for cancer treatment, offering a unique potential to selectively target malignant cells while sparing normal tissues.

In a study published Nov. 10 in Nature, the researchers described how they packed two different therapies into a single oncolytic virus—a virus that is used to destroy cancer cells—to hit GBM ...

Results showed the oncolytic virus combination therapy induced RCB 0 pathologic complete responses in 16 of 37 women, for an estimated 45.9% (90% CI, 32-54) pathologic complete response rate.